Prostamax Peptide

Prostamax is a prostate-focused peptide bioregulator from the Russian “peptide bioregulator” tradition — described as a short peptide (reported as Lys-Glu-Asp-Pro) or prostate peptide complex, studied for prostate tissue health.

How Prostamax works

Prostamax is positioned within the peptide-bioregulator framework as a tissue-specific regulator of prostate function — proposed to help normalise prostate tissue and modulate gene expression in a prostate-selective way. In preclinical models, related peptides reduced prostatic hyperplasia, inflammation and swelling. These are proposed, preclinical mechanisms rather than confirmed human effects.

What the research shows

• BPH model (Borovskaya et al., 2014). In a rat model of benign prostatic hyperplasia, the tetrapeptide Lys-Glu-Asp-Pro reduced prostate mass (~24%) and volume (~40%) versus controls.
• Patents. Russian patents document the peptide’s identity and prostate-directed use.

Candour: independent evidence is very limited — findings come almost entirely from Russian preclinical/animal work and patents, with no Western randomised trials or independent replication. Its molecular formula, weight and CAS are vendor-reported and unverified. Use belongs under a physician’s guidance.

Molecular specification

Quality and sourcing

Every batch of Azzurri Wellness Prostamax is compounded through a Registered 503B outsourcing facility under GMP-compliant processes, HPLC-tested for purity and potency, and third-party lab verified. Shipped cold-pack when needed to protect stability.

References

1. Borovskaya T, et al. Experimental Study of Efficiency of Tetrapeptide Lysil-Glutamyl-Aspartyl-Proline Using the Model of Benign Prostatic Hyperplasia. Mod Res Inflamm. 2014;3(3):108–112. DOI

Compiled by the Azzurri Wellness Research Team and checked against the cited literature. Educational only — not medical advice.